These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27780635)

  • 1. Discovery of fluorobenzimidazole HCV NS5A inhibitors.
    Randolph JT; Flentge CA; Donner P; Rockway TW; Patel SV; Nelson L; Hutchinson DK; Mondal R; Mistry N; Reisch T; Dekhtyar T; Krishnan P; Pilot-Matias T; Stolarik DF; Beno DWA; Wagner R; Maring C; Kati WM
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5462-5467. PubMed ID: 27780635
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).
    Wagner R; Randolph JT; Patel SV; Nelson L; Matulenko MA; Keddy R; Pratt JK; Liu D; Krueger AC; Donner PL; Hutchinson DK; Flentge C; Betebenner D; Rockway T; Maring CJ; Ng TI; Krishnan P; Pilot-Matias T; Collins C; Panchal N; Reisch T; Dekhtyar T; Mondal R; Stolarik DF; Gao Y; Gao W; Beno DA; Kati WM
    J Med Chem; 2018 May; 61(9):4052-4066. PubMed ID: 29653491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.
    Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4508-4512. PubMed ID: 27506559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.
    Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
    Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.
    St Laurent DR; Serrano-Wu MH; Belema M; Ding M; Fang H; Gao M; Goodrich JT; Krause RG; Lemm JA; Liu M; Lopez OD; Nguyen VN; Nower PT; O'Boyle DR; Pearce BC; Romine JL; Valera L; Sun JH; Wang YK; Yang F; Yang X; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1976-94. PubMed ID: 23573957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer M; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1954-1957. PubMed ID: 29653894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferrocene-based inhibitors of hepatitis C virus replication that target NS5A with low picomolar in vitro antiviral activity.
    Gadhachanda VR; Eastman KJ; Wang Q; Phadke AS; Patel D; Yang W; Marlor CW; Deshpande M; Huang M; Wiles JA
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3463-3471. PubMed ID: 30290989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.
    Camus G; Xu S; Han B; Lu J; Dvory-Sobol H; Yu M; Cheng G; Miller MD; Doehle BP; Mo H
    Virology; 2018 Jan; 514():134-141. PubMed ID: 29175627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.
    Kwon HJ; Xing W; Chan K; Niedziela-Majka A; Brendza KM; Kirschberg T; Kato D; Link JO; Cheng G; Liu X; Sakowicz R
    PLoS One; 2015; 10(4):e0122844. PubMed ID: 25856426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer MP; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Allard ML; Buckle RN; Gauuan PJ; Holst CL; Martin GS; Naicker KP; Vellekoop S; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1475-9. PubMed ID: 26850003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
    Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE
    Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
    Gottwein JM; Pham LV; Mikkelsen LS; Ghanem L; Ramirez S; Scheel TKH; Carlsen THR; Bukh J
    Gastroenterology; 2018 Apr; 154(5):1435-1448. PubMed ID: 29274866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.
    Coburn CA; Meinke PT; Chang W; Fandozzi CM; Graham DJ; Hu B; Huang Q; Kargman S; Kozlowski J; Liu R; McCauley JA; Nomeir AA; Soll RM; Vacca JP; Wang D; Wu H; Zhong B; Olsen DB; Ludmerer SW
    ChemMedChem; 2013 Dec; 8(12):1930-40. PubMed ID: 24127258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of hepatitis C virus NS5A inhibitors.
    Lemm JA; O'Boyle D; Liu M; Nower PT; Colonno R; Deshpande MS; Snyder LB; Martin SW; St Laurent DR; Serrano-Wu MH; Romine JL; Meanwell NA; Gao M
    J Virol; 2010 Jan; 84(1):482-91. PubMed ID: 19812153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.
    Kazmierski WM; Baskaran S; Walker JT; Miriyala N; Meesala R; Beesu M; Adjabeng G; Grimes RM; Hamatake R; Leivers MR; Crosby R; Xia B; Remlinger K
    J Med Chem; 2020 Apr; 63(8):4155-4170. PubMed ID: 32202782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines.
    Robinson M; Tian Y; Pagratis N; Delaney WE
    Curr Protoc Microbiol; 2011 Aug; Chapter 17():Unit17.7. PubMed ID: 21805689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.